Researcher

Yongqian Shu

Jiangsu Province Hospital

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 5, 2026 · JOURNAL ARTICLE

Efficacy and Safety of DVDMS ‐Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial

Cancer Science

Phase II trial with modest sample size showing acceptable safety profile and 40% response rate for dysphagia in advanced esophageal cancer, but requires larger confirmatory studies before clinical adoption.

PromisingShegan Gao Yongqian Shu Hao Chen

Reported

Overall response rate (esophageal)40.0%

Median overall survival9.51 months

95% CI for median OS5.45–NE

AUG 10, 2026 · JOURNAL ARTICLE

A predictive model for immunotherapy efficacy in cancer based on dynamic changes of CD8+ T cells: a pan-cancer retrospective study

Frontiers in Immunology

Retrospective single-cohort study with internal validation showing CD8+ T cell dynamics predict immunotherapy outcomes via a novel risk model, but lacks external validation and prospective design needed to change practice.

PromisingYongqian Shu Immunotherapy and Immune Responses Jun Zhang

Reported

Hazard ratio for decreased CD8+ T…0.2308

95% CI for CD8+ T cell HR0.0875–0.5636

Time-dependent AUC at 2.5 months0.727